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Benzofuroxan derivatives N-Br and N-I
induce intrinsic apoptosis in melanoma
cells by regulating AKT/BIM signaling and
display anti metastatic activity in vivo
C. F. Farias1, M. H. Massaoka1, N. Girola1, R. A. Azevedo2, A. K. Ferreira3, S. D. Jorge2, L. C. Tavares4,
C. R. Figueiredo1 and L. R. Travassos1*
Abstract
Background: Malignant melanoma is an aggressive type of skin cancer, and despite recent advances in treatment,
the survival rate of the metastatic form remains low. Nifuroxazide analogues are drugs based on the substitution of
the nitrofuran group by benzofuroxan, in view of the pharmacophore similarity of the nitro group, improving
bioavailability, with higher intrinsic activity and less toxicity. Benzofuroxan activity involves the intracellular
production of free-radical species. In the present work, we evaluated the antitumor effects of different
benzofuroxan derivatives in a murine melanoma model.
Methods: B16F10-Nex2 melanoma cells were used to investigate the antitumor effects of Benzofuroxan derivatives in
vitro and in a syngeneic melanoma model in C57Bl/6 mice. Cytotoxicity, morphological changes and reactive
oxygen species (ROS) were assessed by a diphenyltetrasolium reagent, optical and fluorescence microscopy,
respectively. Annexin-V binding and mitochondrial integrity were analyzed by flow cytometry. Western
blotting and colorimetry identified cell signaling proteins.
Results: Benzofuroxan N-Br and N-I derivatives were active against murine and human tumor cell lines, exerting
significant protection against metastatic melanoma in a syngeneic model. N-Br and N-I induce apoptosis
in melanoma cells, evidenced by specific morphological changes, DNA condensation and degradation, and
phosphatidylserine translocation in the plasma membrane. The intrinsic mitochondrial pathway in B16F10-Nex2 cells is
suggested owing to reduced outer membrane potential in mitochondria, followed by caspase −9, −3 activation and
cleavage of PARP. The cytotoxicity of N-Br and N-I in B16F10-Nex2 cells is mediated by the generation of ROS, inhibited
by pre-incubation of the cells with N-acetylcysteine (NAC). The induction of ROS by N-Br and N-I resulted in the
inhibition of AKT activation, an important molecule related to tumor cell survival, followed by upregulation of BIM.
Conclusion: We conclude that N-Br and N-I are promising agents aiming at cancer treatment. They may be useful in
melanoma therapy as inducers of intrinsic apoptosis and by exerting significant antitumor activity against metastatic
melanoma, as presently shown in syngeneic mice.
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Background
Nifuroxazide is a nitroheterocyclic drug belonging to the
5-nitrofuran’s family and used in the treatment of infec-
tious diseases with frequent symptoms of diarrhea and
colitis, caused by Salmonella spp, Escherichia coli and
Klebsiella [1]. 5-Nitrofurans although being constituents
of widely used medications, may cause toxic side effects
such as polyneuropathy, depression, forgetfulness, alco-
hol intolerance, headaches as well as gastrointestinal
complications, which interfere with their use [2]. In this
context, nifuroxazide analogues were developed replacing
the nitrofuran group by benzofuroxan based on the
pharmacophore similarity attributed to the nitro group,
and also to improve bioavailability, with higher intrinsic
activity and less toxicity [2]. Benzofuroxan as well as 5-
nitrofurans are used as antibacterial and antiparasitic
drugs, giving rise to free radical species [3]. The use of anti-
tumor agents that elevate ROS generation has been effect-
ive in many cases with low resistance to these agents [4].
Melanoma is a deadly type of cancer that results from
the malignant transformation and uncontrolled prolifer-
ation of melanocytes. It is the most invasive skin cancer
with increasing incidence and poor prognosis in the
metastatic stage [5, 6]. Melanoma of the skin has an in-
cidence of 25,2 % per 100.000 individuals with the US
mortality of 3.1 % [7, 8]. Efficient treatment requires
early diagnosis, because of the poor prognosis of the
disease, especially when it reaches the metastatic stage
[9]. With the recent advances in treatment, the 5-year
survival rate in melanoma went up to 91 % although that
of metastatic melanoma is still averaging 15–20 % of
patients. Novel therapeutic approaches are still needed,
especially for the metastatic form.
Cancer cells frequently exhibit changes in the redox
status associated with increased basal production of
ROS, and thus cannot tolerate further intracellular in-
crease of free radicals [4]. Drugs that interfere in redox
changes are, therefore, a promising strategy to overcome
cancer cell resistance to chemotherapy. Redox status
changes may, indeed, exert a critical impact on necrotic/
apoptotic and normal cellular processes.
In the present study, we explored the capacity of nifur-
oxazide analogues to induce ROS-mediated apoptosis in
B16F10-Nex2 murine melanoma cells. The signaling
pathway affected by the benzofuroxan compounds
showed downregulation of Akt and over-expression of
pro-apoptotic BIM. A therapeutic protective effect of
these compounds in a melanoma syngeneic model is
also reported.
Methods
Chemicals
The benzofuroxan drugs were synthetized at the Bio-
chemical and Pharmaceutical Technology Department,
University of São Paulo, as described [10, 11]. The struc-
ture and the substituent groups are indicated below
(Table 1). Stock solutions were prepared in DMSO
(Sigma-Aldrich, St. Louis, USA) at 10 mM and stored in
aliquots at −80 °C. For in vitro tumor cell treatment the
stock solution was diluted in RPMI (Sigma-Aldrich, St.
Louis, USA), and in PBS 15 % Ethanol (Merck) for in
vivo experiments.
Cell lines
The B16F10 murine melanoma cell line is syngeneic in
C57Bl/6 mice and was originally obtained from the Ludwig
Institute for Cancer Research (LICR), São Paulo branch.
The melanotic subline Nex2 (B16F10-Nex2) was isolated
at the Experimental Oncology Unit (UNONEX) and
deposited at Banco de Células do Rio de Janeiro (BCRJ)
no. 0342. Human cervical carcinoma (HeLa), and human
ovarian cancer (Ovcar-3) and the glioblastoma cell line
(U87) were provided by Drs. Hugo P. Monteiro, UNIFESP
and Osvaldo K. Okamoto, University of São Paulo, re-
spectively. Human colon carcinoma (HCT) was from
LICR and mouse colon carcinoma (CT26) was a gift from
Prof. Guillermo Mazzolini, Austral University, Argentina.
Tumor cell lineages were maintained in RPMI 1640,
pH 7.2, supplemented with 10 mM N-2-hydroxyethylpi-
perazine-N′-2-ethanesulfonic acid (HEPES), 24 mM so-
dium bicarbonate, 10 % heat-inactivated fetal bovine
serum (FBS) from Gibco (Minneapolis, MN, USA) and
40 μg/ml gentamicin sulfate (Hipolabor Farmacêutica,
Table 1 Benzofuroxan compounds and derivatives
Compound R1 R2 R3 Compound R1 R2 R3
1 H H H 13 N(CH3)2 H H
2 CH3 H H 14 n-C4H9 H H
3 NH2 H H 15 tert-C4H9 H H
4 OH H H 16 OC3H7 H H
5 F H H 17 Cl H Cl
6 CN H H 18 Cl Cl H
7 CH2CH3 H H 19 CF3 H H
8 OCH3 H H 20 OC4H9 H H
9 Cl H H 21 Br H H
10 COCH3 H H 22 SO2NH2 H H
11 n-C3H7 H H 23 I H H
12 Iso-C3H7 H H
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Sabará, MG, Brazil). Human fibroblasts (GM637 and
Fibro T75) were provided by Dr. Luis F. Lima Reis of
Sirio-Libanez Hospital, São Paulo, and were grown in
DMEM supplemented with 10 mM HEPES, 24 mM
sodium bicarbonate, 10 % FBS, and 40 μg/ml gentamicin
sulfate.
Cell viability assay
Viable cells were assessed using the 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, St. Louis, MO) assay. Melanoma cell
line B16F10-Nex2 (1.0 × 104 cells/well) were seeded on
96-well plates in RPMI supplemented with 10 % FBS,
and compounds (1.5, 3.12, 6.25, 12.5, 25.0, 50.0 or
100 μM) or fresh medium (for control cells) was added.
After 16 h, MTT solution (5 mg/ml) in 1x phosphate-
buffered saline (PBS) was directly added to the cells,
followed by incubation for 4 h at 37 °C. Absorbance was
measured at 570 nm with an automated spectrophoto-
metric plate reader (SpectraMax-M2, Molecular Devices
Software Pro 5.4, Sunnyvale, CA). The experiments were
performed in triplicate. Cell viability was expressed as
percent values in comparison with untreated cells.
DNA degradation
B16F10-Nex2 cells (5 × 105 cells/well) cultured on 6-well
plates, were treated with benzofuroxan derivatives N-Br/
N-I at IC50 and at 100 μM or left untreated at 37 °C for
24 h. Cells were lysed in TELT buffer (50 mM Tris–HCl
pH 8.0, Triton X-100 0.4 %, 2.5 mM EDTA pH 9.0, and
2.5 M LiCl). The lysate was centrifuged (12,000 g) for
20 min at 4 °C. Buffer-equilibrated phenol was added
(1:1, v/v), followed by centrifugation and addition of
chloroform (1:1, v/v). After centrifugation (15 min;
12,000 g; 4 °C), the aqueous phase was precipitated
with sodium acetate 3 M, pH 7.0 and absolute ethanol
(1:0.1:2.5, v/v/v) after overnight incubation at −80 °C.
Precipitated DNA was pelleted and diluted in 50 mg/
ml of RNAse-A (Invitrogen, Carlsbad, CA). The ex-
tracted DNA was subjected to electrophoresis on 1 %
Agarose gel with ethidium bromide (0.5 mg/ml) in
TBE buffer (2 mM EDTA, 90 mM Tris–HCl, 90 mM
boric acid, pH 8.0) at 100 V. One thousand base pair
(1 kb) ladder molecular weight markers (Gibco, Grand
Island, NY) were used. After electrophoresis, DNA
was photographed by UVItec Alliance gel documenta-
tion system (UVItec, Cambridge, UK).
N-acetylcysteine (NAC) effects
B16F10-Nex2 melanoma cells (1.0 × 104/well) were
seeded on 96-well plates in RPMI and 10 % FBS,
and derivative compounds at 1.5, 3.12, 6.25, 12.5,
25.0, 50.0, or 100 μM were added simultaneously
with NAC at 5 mM for 16 h. After incubation, MTT
(5 mg/ml) in 1x phosphate-buffered saline (PBS) was
directly added to the cells, followed by incubation
for 4 h at 37 °C. Absorbance was measured spectro-
photometrically (SpectraMax-M2, Molecular Devices
Software Pro 5.4, Sunnyvale, CA) at 570 nm. Cell
viability was expressed as percent values in compari-
son to untreated cells.
ROS determination
Superoxide anions were assessed by dihydroethidium
(DHE) assay performed according to manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Briefly, 1.0 ×
104cells were cultivated on Hi-Q4 dish and treated
with N-Br/N-I at IC50 for 6 h at 37 °C. Analysis by
fluorescence microscopy was carried out in Nikon BioSta-
tion IM microscope. Images were processed with ImageJ
(http://rsb.info.nih.gov/ij/).
Annexin V and propidium iodide labeling
B16F10-Nex2 cells (5 × 105/well) were grown in 6-well
plates and further incubated with N-Br/N-I at IC50 and
at 100 μM, or with RPMI 10 % FBS (control) for 24 h at
37 °C. Treated and untreated cells were washed three
times with PBS and harvested with a cell scraper. Apop-
totic/necrotic cells were detected using the Annexin V-
FITC Apoptosis Detection Kit (Sigma-Aldrich, St. Louis,
MO). Cells were incubated with binding buffer (10 mM
HEPES/NaOH, pH 7.5, 140 mM NaCl and 2.5 mM
CaCl2) in presence of propidium iodide (PI) and FITC-
labeled annexin V (AV) for 10 min at room temperature
and analyzed by flow cytometry (BD Bioscience FACS-
Canto II, Franklin Lakes, NJ), using FlowJo software
(TreeStar Inc., Ashland, OR).
Chromatin condensation analysis
Murine melanoma cells (1.0 × 104) were cultivated over-
night on Hi-Q4 dish and incubated with N-Br/N-I at IC50
for 24 h. They were then stained with 1.25 μM Hoechst
33342 (Invitrogen, Carlsbad, CA) for 10 min, washed with
PBS and examined for the state of chromatin. Analysis by
time-lapsed fluorescence microscopy was carried out on a
Nikon BioStation IM microscope. Images were processed
with ImageJ (http://rsb.info.nih.gov/ij/).
Mitochondrial membrane potential (Δψm)
The cationic lipophilic dye tetramethylrhodamine
ethyl ester (TMRE) enters the cell in the form of an
ester that is subsequently hydrolyzed and converted to
tetramethylrhodamine, which is reversibly accumu-
lated in the negatively charged mitochondrial matrix
depending on Δψm . B16F10-Nex2 cells (1.0 × 105)
were cultured in 12-well culture plate and incubated
with N-Br/N-I at IC50 for 6 h at 37 °C. Cells were
washed with PBS and labeled with 20 nM TMRE
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(Molecular Probes, OR, USA) for 10 min at 37 °C.
Cells were detached with PBS/Trypsin/EDTA and the
fluorescence was measured on FACSCanto II (BD Bio-
science, Franklin Lakes, NJ), using FACSDiva software
(BD Bioscience, Franklin, NJ) and analyzed using FlowJo
software (TreeStar Inc., Ashland, OR, USA).
Cell lysate extracts and Western blotting
B16F10-Nex2 cells (1.0 × 106) treated with N-Br/N-I at
IC50 and 100 μM or with RPMI 10 % FBS (control cells)
for 6 h or 16 h, were washed with PBS and lysed for
protein extraction with RIPA buffer (50 mM Tris–Cl,
pH 7.5, 150 mM NaCl, 1 % Nonidet P-40, 0.5 % sodium
deoxycholate, and 0.1 % SDS) supplemented with protease
and phosphatase inhibitors (Sigma–Aldrich, St. Louis,
MO). Lysates from cells co-incubated with 5 mM NAC
and exposed to derivatives at IC50 were also obtained and
subjected to Western blotting as described below.
Cell lysates were transferred to microcentrifuge tubes,
and kept on ice for 1 h with shaking. They were soni-
cated for 10 min and centrifuged at 14,000 g for 15 min.
Protein concentration of lysates was determined by BSA
quantification assay (Thermo Fisher Scientific, Rockford,
IL). Each cell lysate (30 μg protein) was separated by
SDS gel electrophoresis and transferred to nitrocellulose
membrane (Millipore, Billerica, MA), blocked with TPBS
(PBS, 0.05 % Tween-20) and 5 % (w/v) skim milk or
BSA, washed in TPBS and incubated with primary anti-
body for 16 h on 4 °C. Immunoblotting was run with anti-
bodies against Akt, phospho-Akt (thr308), BIM, caspase 9,
caspase 9-cleaved, PARP, PARP-cleaved and β-actin, all
purchased from Cell Signaling Technology (Beverly, MA).
After washing, membranes were incubated with anti-IgG
antibody conjugated with horseradish peroxidase and the
immunoreactive bands were detected using Immobilon
(Millipore, Billerica, MA, USA) under a chemilumines-
cence detection system (UVItec, Cambridge, UK). β-Actin
was used as loading control.
Detection of caspase-3 activity
Active caspase 3 was determined in B16F10-Nex2 cells
(2.5 × 106 cells) grown with N-Br/N-I at IC50, or RPMI
10 % FBS (control) for 8 h. After incubation, cells were
tested with Caspase-3 Assay Kit, Colorimetric (Sigma-
Aldrich, St. Louis, USA) according to manufacturer’s
protocol. Briefly, cells were washed twice with PBS and
resuspended in 25 μL of chilled Cell lysis Buffer for
20 min on ice. The lysates were centrifuged at 20,000 g
for 15 min at 4 °C and 5 μL of the aqueous phase was
incubated with 85 μL Assay Buffer and 10 μL caspase-3
substrate Ac-DEVD-pNA 2 mM at 37 °C for 16 h in a
96-well plate. Absorbance was read at 405 nm in a
microplate reader (SpectraMax-M2, Software Pro5.4,
Molecular Devices, Sunnyvale, CA).
Experimental melanoma models in vivo
C57BL/6 mice were obtained from the Center for Devel-
opment of Experimental Models (CEDEME), Federal
University of São Paulo (UNIFESP). Animal experiments
were approved by the UNIFESP Ethics Committee for
Animal Experimentation (CEUA No. 6641300114) based
on international recommendations. All in vivo experi-
ments were performed at least twice.
In the lung colonization model, male, six-to-eight
week-old, C57BL/6 and NOD/SCID-IL-2R-gamma null
mice were challenged endovenously with 5 × 105 syn-
geneic B16F10-Nex2 melanoma cells in 100 μl of PBS.
Animals (n = 5 per group) were treated 1 day after
tumor challenge, with seven daily intraperitoneal doses
of 300 μg (12 mg/Kg) of each benzofuroxan derivative
or vehicle (PBS 15 % EtOH). After 14 days, lungs were
collected from animals of each group, and the melan-
otic lung nodules were counted.
Statistical analysis
Unless otherwise specified, two independent experiments
were performed in triplicate. Experimental values are
expressed as mean values ± standard deviations (S.D.). For
significance analyses Student’s t-test was used, GraphPad
Prism 4.0 software (La Jolla, CA). p values < 0.05 were
considered significant.
Results
In vitro and in vivo antitumor activity of benzofuroxan
compounds
The cytotoxicity of the compounds (Table 1) and par-
ticularly, the N-Br and N-I derivatives was investigated
primarily on murine melanoma B16F10-Nex2 cells at
100 μM for 16 h. All tested compounds were active
against tumor cells; compounds 1, 5, 10, 17, 18, 19, 21
and 23 were the most cytotoxic (Fig. 1a). The IC50 values
(concentrations needed to kill 50 % of tumor cells) were
determined on B16F10-Nex2, ranging from 6.9 to
25.4 μM (Table 2). They were evaluated with different
murine and human tumor cell lines and non-tumorigenic
cells (Table 3). Derivatives N-Br and N-I exhibited
similar effects with IC50 values between 10 and 30 μM,
except for U87 cells, which were resistant to these
compounds (IC50 > 50 μM).
We also evaluated the antitumor activity of the ben-
zofuroxan compounds in vivo, using a syngeneic lung-
colonization (“metastatic”) murine melanoma model.
Melanoma cells were injected endovenously in C57Bl/6
mice and treatment was carried out with 7-daily i.p. in-
jections of 300 μg of each compound or vehicle control
(PBS 15 % EtOH), starting on day 1 after tumor cell
challenge. We observed that only the 21 and 23 deriva-
tives induced significant protection (p < 0.05) against
metastatic melanoma in vivo (Fig. 1b). Derivatives 21
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Fig. 1 Screening of antitumor activity of benzofuroxan compounds in vitro and in vivo against murine melanoma. a Cytotoxicity of 23
compounds in B16F10-Nex2 cells. Compounds were incubated with tumor cells at 100 μM for 16 h and viability was assessed by MTT
method. b Antitumor activity of active benzofuroxan derivatives in vivo. Number of metastatic melanoma nodules in the lung of animals
after treatment with 500 μM of compounds injected i.p. For each experiment, five animals were used per group (*p < 0.05). c N-Br and N-I
melanoma treatment (300 μg/day) in NOD/SCID IL-2R-gamma null mice for seven consecutive days. No. metastatic nodules were quantified using a
Stereo Microscope (Nikon) (*p < 0.05)
Table 2 IC50 (μM) and standard deviations of different
benzofuroxan compounds acting on murine melanoma
B16F10-Nex2 cells
Compound IC50 SD
1 25.3 ±4.3
5 16.7 ±2.8
10 25.4 ±2.7
17 19.6 ±2.0
18 6.9 ±0.3
19 9.7 ±0.5
21 16.5 ±0.9
23 12.0 ±0.4
Table 3 IC50 values obtained for N-Br and N-I treatment of
different tumor cells and non-tumorigenic cell lineages
IC50 (μM)
Cell lineage N-Br N-I
B16F10-Nex2 16.5 ± 0.9 12.0 ± 0.4
HCT 32.2 ± 6.6 21.4 ± 3.8
U87 49.1 ± 5.5 58.7 ± 1.4
HeLa 21.7 ± 6.4 25.6 ± 7.2
CT26 34.7 ± 5.8 26.4 ± 4.1
Ovcar-3 18.1 ± 1.9 17.3 ± 3.0
Fibro T75 27.7 ± 2.1 20.6 ± 1.6
GM637 9.4 ± 2.0 9.1 ± 4.3
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and 23 (N-Br and N-I), are named 4-Bromo-[N′-(ben-
zofuroxan-5-yl)methylene]benzohydrazide (N-Br) and
4-Iodo-[N′-(benzofuroxan-5-yl)methylene]benzohydra-
zide (N-I), respectively.
The effects in C57Bl/6 immunocompetent mice of N-Br
and N-I were reproduced also in immune deficient NOD/
SCID/IL-2R-gammanull mice [12], which lack T, B and NK
cells and circulating complement. As shown in Fig. 1c,
both N-Br and N-I significantly reduced the development
of pulmonary tumor nodules after 14 days. During the ex-
periment period, all animals maintained healthy physical
appearance, normal activity and weight, showing no tox-
icity of both compounds.
Morphological changes in melanoma cells treated with
N-Br and N-I
Both N-Br and N-I caused morphological alterations in
B16F10-Nex2 melanoma cells, with cytoplasm retrac-
tion, round cells and loss of tumor cell adhesion (Fig. 2a).
DNA condensation and fragmentation were also ob-
served in treated cells. Melanoma cells were incubated
with both compounds at the IC50 concentration for 24 h
and the density of nuclear chromatin previously stained
with Hoechst was assessed by fluorescence microscopy
(Fig. 2b). The relative intensity of fluorescence was
quantified by processing images with ImageJ software
(Fig. 2c). As to DNA fragmentation, the ladder pattern
Fig. 2 Benzofuroxan derivative effects on melanoma cells (a) Morphological effects. Arrows point to surface membrane alterations. Original
magnifications, 100× left panels; 200× right panels; 400x inserts. b DNA condensation induced by N-Br and N-I. Yellow arrows indicate positive
cells for Hoechst staining. 100×, and 400× inserts. c Quantification of Hoechst 33342 relative fluorescence in treated and control cells, shown in B;
**p≤ 0.001; *p≤ 0.05 (d) DNA fragmentation showing a ladder pattern; A: Control; B: N-Br (16 μM); C: N-I (12 μM); D: N-Br (100 μM); E: N-I (100 μM)
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was observed using Agarose gel electrophoresis, upon
treatment with both compounds at 100 μM during 24 h
of incubation (Fig. 2d).
Apoptosis evidence in melanoma cells treated with N-Br
and N-I
Chromatin condensation and DNA degradation together
with phosphatidyl serine translocation to the outer
membrane [13] and some characteristic morphological
traits (cytoplasm retraction, blebs) are common events
of tumor cell apoptosis. We have observed that in
addition to the nuclear events, N-Br and N-I cytotox-
icity involved significant levels of dose dependent
phosphatidylserine accumulation on the outer mem-
brane of B16F10-Nex2 cells, as shown by annexin-V
cytometry (Fig. 3a). The number of early apoptotic cells
(annexin V+/PI−) increased as compared to untreated
control cells. The treatment with N-Br and N-I at IC50
concentration (16 μM for N-Br and 12 μM for N-I)
induced apoptosis in 15.2 and 17.2 % of tumor cells
respectively. When tested at 100 μM the apoptosis ratio
increased to 34.3 % for N-Br and 39.9 % for N-I. Nega-
tive control cells showed a very low ratio of annexin-V
positive cells (2.8 %).
The role of caspases in tumor cell death by apoptosis
is well known, although there are also reports of caspase
Fig. 3 Apoptotic effects of N-Br and N-I in B16F10-Nex2 cells (a) Phosphatidylserine translocation determined by annexin V. b Caspase-3 activation
determined by colorimetric assay (*p < 0,05). c Evaluation of caspase-9 and cleavage of PARP induced by the benzofuroxan derivatives
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independent apoptosis [13]. Caspase-3 can be activated
in both the intrinsic and extrinsic apoptotic pathways
[14]. After treatment of B16F10-Nex2 cells for 6 h with
N-Br and N-I, the levels of caspase-3 increased 2 and
2.4-fold as compared to untreated cells (Fig. 3b).
The involvement of other caspases was investigated by
Western blotting and both N-Br and N-I activated
caspase-9. Moreover, the cleavage of PARP was also ob-
served in treated cells (Fig. 3c).
N-Br and N-I induce tumor cell death through oxidative
stress followed by disruption of Δψm
ROS may damage cellular components and trigger a cas-
cade of events leading to cell death [15]. Previous studies
with benxofuroxan compounds have shown that these
molecules are able to elicit ROS dependent oxidative
stress [16]. B16F10-Nex2 cells treated for 6 h with IC50
concentrations of the benzofuroxan compounds (16 μM
for N-Br and 12 μM for N-I), in presence or absence of
NAC, were examined for intracellular ROS revealed with
DHE probe. Both compounds led to increased ROS for-
mation evaluated by fluorescence microscopy, as com-
pared to untreated cells, and this effect was attenuated
by NAC (Fig. 4a). ROS dependent cell death was further
confirmed in a cytotoxicity assay of melanoma cells and
the cytotoxic effects of N-Br and N-I were significantly
inhibited by NAC (Fig. 4b).
The integrity of ΔΨm, tested by using the lipophilic cat-
ionic dye TMRE, was examined in cells treated with the
benzofuroxan derivatives [17]. N-Br and N-I significantly
Fig. 4 ROS generation and N-acetyl cysteine protective effects. a ROS generation after treatment of melanoma cells with N-Br, N-I and NAC, as
detected by DHE fluorescence microscopy. **p≤ 0.001; *p≤ 0.05 (b) Role of ROS on the induction of apoptosis in B16F10-Nex2 cells by the
benzofuroxan derivatives and protection by NAC. Cellular viability was assessed by MTT assay. c Evaluation of Δψm as affected by N-Br
and N-I treatment. ΔΨm was assessed using TMRE by flow cytometry
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decreased the intensity of mitochondrial fluorescence in
15,8 and 9,7 % respectively, indicating that both com-
pounds elicited dissipation of ΔΨm after 6 h of treatment.
When tumor cells were incubated with NAC, mitochon-
dria were protected from the cytotoxic effects of both
compounds (Fig. 4c).
N-Br and N-I exert down regulation of AKT and upregulation
of BIM in melanoma cells
AKTactivation is involved in the tumorigenesis and resist-
ance to conventional anticancer therapies [18]. In melan-
oma cells treated with N-Br and N-I, phosphorylation of
Akt at Thr380 was reduced, as seen in Western blotting
(Fig. 5). Down regulation of active Akt is accompanied by
the expression of genes regulating apoptosis. One of these,
BIM, encodes a member of “BH3-only proteins”, an im-
portant group of pro-apoptotic molecules responsible for
mitochondrial stress-induced apoptosis [19, 20]. BIM
levels increased in melanoma cells after 6 h treatment
with 16 μM of N-Br and 12 μM of N-I (Fig. 5). Indirectly,
the involvement of ROS on BIM expression was evaluated
by co-incubation of B16F10-Nex2 cells with NAC
(5 mM). The reducing activity of NAC restored Akt activ-
ity and the expression of BIM was not detected. Therefore,
this result shows that the modulation of AKT/BIM signal-
ing depends on ROS generation during the treatment of
B16F10-Nex2 cells with the benzofuroxan compounds.
Discussion
In the current study, we report on the promising antitu-
mor effects of benxofuroxan compounds, which have been
shown to induce apoptosis in B16F10-Nex2 melanoma
cells. The antibacterial, antiprotozoan and anticancer ef-
fects of nifuroxazide related drugs [1], depend on ROS
generation [21], and in the present work, we evaluated the
antitumor effects of 23 compounds that have the nitrofu-
ran system replaced by a benzofuroxan molecule.
All 23 benzofuroxan compounds exhibited significant
levels of cytotoxicity against murine melanoma B16F10-
Nex2 cells, and two of them, N-Br and N-I, are the most
promising derivatives with antitumor activity in vitro
and in vivo. N-Br and N-I exhibited potent cytotoxic ac-
tivity not only in murine melanoma, but also against
several other murine and human tumor cell lines, dem-
onstrating a therapeutic potential in different types of
cancers. There was little difference in the IC50 values in
tumor cells and non-tumorigenic cells, including melan-
a (unpublished results), but primary normal cells have
not been tested. Cultured cells in the laboratory differ
from cells in a living organism in many aspects. Both
compounds did not exhibit toxicity in vivo at the con-
centrations used and yet showed definite antitumor ef-
fects in syngeneic mice.
Both N-Br and N-I compounds induced several effects
on melanoma cells, related to apoptosis, such as
rounding-up, reduction of cellular and nuclear volume,
chromatin condensation and DNA fragmentation, and
phosphatidylserine outer membrane expression [22, 23].
The loss of ΔΨm, activation of caspase 9 and 3, followed
by cleavage of PARP are characteristics of intrinsic apop-
tosis [24], and were observed upon incubation of N-Br
and N-I with melanoma cells.
Given the nature of the benzofuroxan compounds,
they increased the levels of ROS in tumor cells [3]. Since
co-incubation with the antioxidant N-acetyl cysteine
inhibited ROS generation, benzofuroxan drug cytotox-
icity and the loss of ΔΨm, we conclude that production
of ROS induced by both N-Br and N-I derivatives is in-
volved in their antitumor activity in B16F10-Nex2 cells.
Due to their reactive potential, ROS can oxidize DNA
bases, leading to DNA strand breaks, intra-strand ad-
ducts, crosslinks and mutations [25]. ROS can affect the
integrity of proteins and/or lipids in membranes, decreas-
ing the fluidity and increasing membrane permeability as
in mitochondria [4]. Mitochondrial dysfunction, charac-
terized by loss of transmembrane potential and opening
of mitochondrial permeability transition pores occurs
via many apoptotic stimuli [22]. The benzofuroxan
derivatives caused disruption of ΔΨmin melanoma cells
after 6 h incubation. Impairment of mitochondrial
membrane permits the release of cytochrome c, an
event known to occur after externalization of phospha-
tidylserine [23], triggering the apoptotic intrinsic path-
way with activation of caspase 9 and 3 [26]. As shown,
the apoptotic effects of both benzofuroxan derivatives
involved caspase activation.
In addition, N-Br and N-I compounds induced Akt in-
activation and expression of pro-apoptotic BH3 protein
BIM. Akt is a serine/threonine protein kinase downstream
Fig. 5 Expression of p-AKT and BIM in B16F10-Nex2 cells treated
with N-I and N-Br, assessed by Western blotting. B16F10-Nex2 were
treated with both compounds at IC50 for 6 h in presence or absence
of NAC. Β-actin was used as loading control
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target of the phosphatidylinositol 3-kinase (PI3K) signal-
ing pathway, a central player in response to growth factors
or insulin and contribute to several cellular functions
including nutrient metabolism, cell growth, transcriptional
regulation and cell survival [27]. In a wide variety of
cancers, Akt is frequently over activated, contributing to
malignancy and related with tumor aggressiveness [18].
Phosphorylation of Akt at Thr308 is essential for Akt
catalytic activity [28]. In melanoma, Akt promotes tumor
progression, escape from apoptosis and enhanced survival
[29]. Recent works have reported that oxidative stress can
modulate Akt activation [29–31]. Luo et al. reported that
enhanced ROS interact with AKT/FoxO3a/BIM causing
inhibition of Akt and consequently nuclear accumulation
of FoxO3a, thus facilitating transcription of the target
gene BIM [32].
Our results contribute to elucidate the link between Akt
signaling and ROS generation. Immunoblotting analysis
showed a high expression of phospho-Akt in untreated
melanoma cells that was down regulated after treatment
with both benzofuroxan derivatives. Co-incubation with
NAC blocked these effects suggesting that ROS generation
induced in melanoma cells acted as a mediator. Another
intracellular signaling molecule sensitive to redox modula-
tion was BIM, which belongs to pro-apoptotic BH3-only
proteins family. Consistent with Lou et al. findings [32],
downregulation of Akt and increased expression of BIM,
which binds to the Bcl-2 family members, led to the loss
of ΔΨm [24], thus triggering the intrinsic apoptosis in
melanoma cells.
Conclusion
In conclusion, the present work indicates that benzofur-
oxan compounds are promising molecules with significant
antitumor activities in vitro and in vivo, which should be
considered as new therapeutic agents against malignant
melanoma.
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